What's The Price For Marketing A DESI Drug? Solvay Settles Estratest Class Action for $30 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Settlement in California follows claim that the hormone replacement therapy was in fact unapproved; a similar action is pending in Minnesota.
You may also be interested in...
Product Liability Forecast: More Suits, Smaller Scale
More than 20 drugs are the subject of multidistrict product liability litigation, but none of the pending cases approach the scope of past lawsuits against Merck’s Vioxx and Lilly’s Zyprexa. That may be one silver lining for Big Pharma as the blockbuster era draws to a close.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.